By Fineline Cube 
Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management Co., Ltd., Sirnaomics, and the Fuyang Economic and Technological Development Zone Management Committee signed a framework agreement to launch a RMB 300 million ($42 million) Small Nucleic Acid Industry Fund. The fund will be registered in Fuyang, Hangzhou, and managed by Xinyuan Zhenghe to support the entire oligonucleotide industry chain.
Fund Structure
| Component | Details |
|---|---|
| Fund Size | RMB 300 million (≈ USD 42 million) |
| Location | Fuyang, Hangzhou |
| Manager | Xinyuan Zhenghe (Hangzhou) Private Equity Fund Management |
| Key Partners | Fuyang Economic & Technological Development Zone, Sirnaomics |
| Focus Area | Small nucleic acid (oligonucleotide) industry chain |
| Registration | December 2025 |
Investment Objectives
| Objective | Scope |
|---|---|
| Pipeline Support | Accelerate development of Sirnaomics’ core clinical pipelines |
| Broad Coverage | Invest in small nucleic acid tech applications and innovative drugs for oncology and CNS |
| Technological Advancement | Fund emerging nucleic acid technology projects |
Strategic Implications
- For Sirnaomics: Non‑dilutive funding accelerates clinical pipelines; aligns with RNA therapeutics leadership; leverages regional government support.
- For Fuyang Zone: Attracts high‑value biotech investment; positions Hangzhou as RNA innovation hub; creates jobs and tax revenue.
- For Market: RMB 300 million fund signals strong policy support for oligonucleotide sector; addresses manufacturing and R&D gaps in China’s RNA ecosystem.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding fund deployment, pipeline advancement, and market impact. Actual results may differ due to regulatory changes, competitive dynamics, or investment performance.-Fineline Info & Tech